Skip to main content

CHAMPION-AF Clinical Trial

Active, not recruiting · Not applicable · NCT04394546

Conditions: Atrial Fibrillation, Stroke, Bleeding

At a glance

Research payments reported, 2025
$2.3M
U.S. investigators named
97
Sites paid
93
Planned or actual enrollment
3,000

About the trial

Sponsor
Boston Scientific Corporation
Tested
WATCHMAN FLX LAAC Device (device), Non-Vitamin K Oral Anticoagulant (drug)
Dates
Started 2020-10-15; completion 2027-12
Results posted
Not yet

The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $2.3M in research payments for this study in 2025 (952 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.